UNIVERSAL TECHNICAL INSTITUTE INC (UTI) Stock News

A class action lawsuit has been filed against ARS Pharmaceuticals (NYSE:SPRY) for allegedly providing misleading statements about expanded insurance coverage for its epinephrine nasal spray product 'neffy' with CVS Caremark. The company reportedly expressed confidence that coverage would begin July 1, 2026, while failing to disclose risks of delays that would impact summer and back-to-school seasons. Investors who purchased ARS securities between March 9 and June 24, 2026 can apply to be lead plaintiff by October 5, 2026.

A securities class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors who purchased securities between December 17, 2025 and July 6, 2026. The lawsuit alleges the company made materially false and misleading statements regarding business operations, growth prospects, and financial stability, causing securities to trade at artificially inflated prices. Investors who suffered losses are encouraged to contact the law firm or submit claims by September 28, 2026 to potentially serve as lead plaintiff.

Law firm Kirby McInerney LLP is investigating potential securities fraud claims against Alnylam Pharmaceuticals following the company's announcement on July 30, 2026, that it lowered TTR product sales guidance by approximately $200 million due to normalization of growth in the ATTR-CM market after satisfying pent-up demand. The stock fell 28% ($81.14 per share) to $205.48 on the news.

Dimensional Fund Advisors Ltd. disclosed a 1.41% stake in Advanced Medical Solutions Group PLC comprising 3,110,204 ordinary shares as of June 22, 2026. The disclosure includes a single purchase transaction of 112 shares at 22.3150 GBP per unit. Dimensional expressly disclaims beneficial ownership and notes it lacks discretion over 32,163 of the disclosed shares.

GSK and Spero Therapeutics announced FDA approval of Utebzi (tebipenem pivoxil hydrobromide), the first oral carbapenem antibiotic for treating complicated urinary tract infections including pyelonephritis. The drug demonstrated non-inferiority to intravenous imipenem-cilastatin in Phase 3 trials and is expected to launch in the U.S. by end of 2026, offering an alternative to hospital-based IV treatments for the 3+ million Americans annually affected by cUTIs.

GSK plc (NYSE: GSK ) and Spero Therapeutics, Inc. (NASDAQ: SPRO ) announced on Wednesday that the U.S. Food and Drug Administration has approved Utebzi (tebipenem pivoxil hydrobromide), an oral antibiotic for adults with complicated urinary tract infections (cUTIs). First Oral Carbapenem Approved For This Patient Population The indication includes pyelonephritis, caused by certain susceptible pathogens, and patients who have limited or no alternative oral treatment options . The companies said Utebzi is the first and only oral carbapenem antibiotic approved for this patient population. The approval stems from GSK’s development and exclusive global licensing agreement with Spero Therapeutics, excluding select Asian territories. Complicated UTIs affect more than 3 million people annually in the U.S., according to the companies. Treatment failure occurs in as many as 34% of patients, while infections caused by multidrug-resistant pathogens contribute more than ... Full story available on Benzinga.com

GO Residential REIT completed acquisitions of 7 Dey Street in Tribeca and Ivy Tower in Times Square, increasing its portfolio to 2,545 residential suites (26% growth). The transactions are expected to be immediately accretive to AFFO per unit and were funded through available cash and $146.3 million in fixed-rate mortgage debt at 4.50%. The REIT approved a monthly cash distribution of $0.05325 per unit for June 2026.

ARCpoint Inc. (TSXV: ARC) has appointed Peter Kendall as Interim Chief Executive Officer for an initial 90-day term to assess the company's business model, MAPL technology platform, and strategic direction. John Constantine has stepped down as CEO to focus on sales, marketing, and commercial development. Kendall will receive 4 million RSUs vesting after 12 months, with potential additional compensation if no continuing engagement is agreed upon.

John Hancock Investment Management announced quarterly distributions for four closed-end funds on June 1, 2026. The funds declared distributions ranging from $0.1535 to $0.6500 per share, with payment scheduled for June 30, 2026. Distributions may include net investment income, capital gains, and return of capital.

John Hancock Investment Management announced monthly distributions for its closed-end funds on June 1, 2026. The Tax-Advantaged Dividend Income Fund (HTD) will distribute $0.1580 per share monthly, while the Premium Dividend Fund (PDT) will distribute $0.0825 per share monthly. All distributions are scheduled for payment on June 30, 2026.

<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css" /> <ul> <li style="list-style-type:none;"> <ul> <li style="text-align:left;"><strong>Total sales increased 14%, on top of 6% last year </strong></li> <li style="text-align:left;"><strong>Comparable store sales increased 6%</strong></li> <li style="text-align:left;"><strong>Net income was $115 million, and diluted EPS was $1.79 </strong></li> <li style="text-align:left;"><strong>Excluding certain expenses associated with bankruptcy acquired leases: </strong> <ul> <li><strong>Adjusted EPS increased 26% to $2.10, well above guidance</strong></li> <li><strong>Full year adjusted EPS guidance is now $11.45 to $11.80<br /><br /></strong></li> </ul> </li> </ul> </li> </ul> <p align="left">BURLINGTON, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Burlington Stores, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/BURL" rel="nofollow">BURL</a>), a nationally recognized off-price retailer of high-quality, branded apparel, footwear, accessories, and merchandise for the home at everyday low prices, today announced its results for the first quarter ended May 2, 2026.</p> <p align="left">Michael O'Sullivan, CEO, stated, "We are pleased with our strong performance in the first quarter. Adjusted EPS grew 26% versus the first quarter of last year, which represented our 14th consecutive quarter of double digit EPS growth. This track record demonstrates our ability to consistently convert sales into operati

Vizsla Silver Corp. has secured a MXN$173 million (approximately US$10 million) unsecured working capital facility from FIFOMI, a Mexican government-backed mining finance institution. The five-year facility will support operating and working capital expenditures for the company's flagship Panuco silver-gold project in Sinaloa, Mexico. The financing represents validation of the project's economic importance and strengthens alignment between Vizsla and the Mexican government.

AllianceBernstein announced distribution rates for two of its closed-end funds. The AllianceBernstein Global High Income Fund (AWF) declared a distribution of $0.0655 per share, while the AllianceBernstein National Municipal Income Fund (AFB) declared $0.05018 per share, both with an ex-date of June 4, 2026 and payment date of June 26, 2026.

A class action lawsuit has been filed against Power Solutions International, Inc. (NASDAQ: PSIX) for allegedly making false and misleading statements about its ability to capture sales demand in the data center market and understating manufacturing capacity enhancement costs. Investors who purchased securities between May 8, 2025 and March 2, 2026 have until May 19, 2026 to apply as lead plaintiff.

Nature's Miracle Holding Inc. has entered into a Memorandum of Understanding with DROMNI Intelligence Technology Ltd. to collaborate on developing and commercializing AI-enabled autonomous robotics solutions for the U.S. agriculture, energy, and data center markets. The partnership will focus on unmanned ground vehicle deployment, smart infrastructure automation, and pilot programs across greenhouse operations, logistics, energy infrastructure, and industrial automation.

Brookfield Bancshares, Inc. and First National Bank of Brookfield announced the execution of a definitive merger agreement to acquire NSTS Bancorp, Inc. and North Shore Trust and Savings in an all-cash transaction valued at approximately $73.7 million. NSTS stockholders will receive $14.28 per share in cash. The transaction is expected to close in Q4 2026, subject to regulatory approvals and stockholder approval. Post-closing, the combined entity will operate four branches in the Chicago-Naperville-Elgin MSA with over $600 million in assets.